Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

22
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
22
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

13
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

15
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
15
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

17
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
17
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

128
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
128

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical and Clinical Boundaries in Genomics & Newborn Screening: A Brief Report from IPIC2025.

International journal of neonatal screening·2026
Same author

Claudio Bordignon.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Topical JAK inhibitor for refractory skin inflammation in STAT1 GOF.

Journal of human immunity·2026
Same author

Precision medicine in paediatrics: Progress and priorities.

British journal of clinical pharmacology·2026
Same author

A roadmap for supporting the development of advanced therapy medicinal products in a European framework.

The Lancet regional health. Europe·2026
Same author

The Homozygous p.(Arg215Ter) Variant in XRCC2 Is Associated With Atypical Fanconi Anemia Without Major Hematological Abnormalities in Childhood.

American journal of medical genetics. Part A·2026

Related Experiment Video

Updated: Aug 11, 2025

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

759

Updated Management Guidelines for Adenosine Deaminase Deficiency.

Eyal Grunebaum1, Claire Booth2, Geoffrey D E Cuvelier3

  • 1Division of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

The Journal of Allergy and Clinical Immunology. in Practice
|February 3, 2023
PubMed
Summary

Adenosine deaminase deficiency causes severe combined immunodeficiency and other health issues. Advances include newborn screening, enzyme replacement therapy, hematopoietic cell transplantation, and gene therapy for improved patient outcomes.

Keywords:
Adenosine deaminase deficiencyEnzyme replacementGene therapyManagementSevere combined immunodeficiencyTransplantation

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.1K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.7K

Related Experiment Videos

Last Updated: Aug 11, 2025

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

759
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.1K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.7K

Area of Science:

  • Immunology
  • Genetics
  • Pediatrics

Background:

  • Inherited adenosine deaminase (ADA) deficiency leads to severe combined immunodeficiency (SCID).
  • ADA deficiency presents with diverse systemic abnormalities beyond infections, including neurodevelopmental, organ-specific, autoimmune, and malignant conditions.
  • Early diagnosis via newborn screening is crucial for timely intervention.

Purpose of the Study:

  • To review recent advances in the management of ADA deficiency.
  • To discuss current and emerging treatment options for ADA-deficient patients.
  • To highlight the importance of long-term follow-up for optimizing treatment strategies.

Main Methods:

  • Review of current literature on ADA deficiency management.
  • Analysis of treatment outcomes for enzyme replacement therapy (ERT), hematopoietic cell transplantation (HCT), and gene therapy.
  • Discussion of diagnostic approaches including newborn screening.

Main Results:

  • Newborn screening enables early diagnosis and treatment of asymptomatic infants.
  • Enzyme replacement therapy (ERT) benefits most patients but can be costly.
  • Allogeneic HCT from matched donors is a preferred treatment; gene therapy offers high survival and engraftment rates when matched donors are unavailable.
  • Reduced-intensity conditioning for HCT with mismatched or unrelated donors shows promising outcomes.

Conclusions:

  • Current management strategies for ADA deficiency have significantly improved patient outcomes.
  • Hematopoietic cell transplantation and gene therapy are effective alternatives to prolonged ERT.
  • Individualized long-term follow-up is essential for determining the optimal treatment pathway for ADA-deficient individuals.